CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Compare capital gains tax exposure between ETFs and index funds in retirement, and choose the option with better tax efficiency.
28,430 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
As investors eye small-cap medical devices, Inogen's INGN 2026 earnings story matters. This analysis breaks down Q1 r...
SBI Holdings and Rakuten are teaming up to build an in-house crypto investment trust as Japan updates its crypto rule...
NVIDIA backs LUMENTUM and COHERENT with a $4B stake to accelerate AI data movement; analysts weigh the upside and ris...
As inflation cools in 2026, Costco and Sprouts diverge on growth and valuation. This story weighs costco sprouts: whi...
Dine Brands (DIN) 2026 presents a pivotal earnings outlook with evolving margins, franchise dynamics, and a path to g...
Alphabet reportedly priced a rare 100-year bond to back AI and data-center expansion, a move that stirs debate on lon...
As 2026 unfolds, Main Street stocks like MAIN reveal how middle-market finance navigates rising rates and credit shif...
A $29 billion AI-linked stock offering goes live this week, setting up a crucial test of investor appetite for AI pla...
Whirlpool faces a challenging 2026 as costs rise and demand shifts. This guide breaks down the whirlpool stock down o...
Ford surprised markets with an upward revision to its 2026 guidance after a solid first quarter. This article breaks ...
SpaceX stock stumbled since its IPO has sparked questions about what comes next. By charting historical IPO patterns ...